Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Total Liabilities: 2020-2025

Historic Total Liabilities for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $657.6 million.

  • Apellis Pharmaceuticals' Total Liabilities fell 1.08% to $657.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $657.6 million, marking a year-over-year decrease of 1.08%. This contributed to the annual value of $656.5 million for FY2024, which is 10.49% up from last year.
  • Per Apellis Pharmaceuticals' latest filing, its Total Liabilities stood at $657.6 million for Q3 2025, which was down 1.13% from $665.1 million recorded in Q2 2025.
  • Apellis Pharmaceuticals' Total Liabilities' 5-year high stood at $841.4 million during Q2 2021, with a 5-year trough of $565.3 million in Q1 2024.
  • For the 3-year period, Apellis Pharmaceuticals' Total Liabilities averaged around $619.0 million, with its median value being $640.2 million (2024).
  • Per our database at Business Quant, Apellis Pharmaceuticals' Total Liabilities skyrocketed by 76.41% in 2021 and then declined by 20.60% in 2022.
  • Apellis Pharmaceuticals' Total Liabilities (Quarterly) stood at $683.1 million in 2021, then decreased by 13.58% to $590.3 million in 2022, then climbed by 0.65% to $594.2 million in 2023, then increased by 10.49% to $656.5 million in 2024, then fell by 1.08% to $657.6 million in 2025.
  • Its last three reported values are $657.6 million in Q3 2025, $665.1 million for Q2 2025, and $643.1 million during Q1 2025.